| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 8888888 |
Internal/system code - not a standard HCPCS code |
4,837 |
2,571 |
$3.37M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,905 |
3,194 |
$284K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,545 |
1,255 |
$115K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,087 |
1,795 |
$96K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
479 |
439 |
$86K |
| 80050 |
General health panel |
305 |
285 |
$59K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,843 |
1,528 |
$45K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
462 |
416 |
$37K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,051 |
947 |
$26K |
| 80053 |
Comprehensive metabolic panel |
3,478 |
2,887 |
$24K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
587 |
518 |
$24K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,144 |
966 |
$21K |
| 81001 |
|
1,538 |
1,312 |
$19K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,304 |
1,073 |
$17K |
| 84443 |
Thyroid stimulating hormone (TSH) |
368 |
348 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
31 |
24 |
$9K |
| 87081 |
|
461 |
435 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
463 |
438 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
165 |
148 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
48 |
46 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
577 |
462 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
193 |
184 |
$4K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,032 |
798 |
$3K |
| 80061 |
Lipid panel |
460 |
430 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
854 |
755 |
$2K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
46 |
41 |
$2K |
| 70450 |
Computed tomography, head or brain; without contrast material |
27 |
25 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
151 |
136 |
$2K |
| 85027 |
|
14 |
13 |
$2K |
| 84484 |
|
541 |
460 |
$2K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
70 |
48 |
$1K |
| 96376 |
|
16 |
12 |
$1K |
| 87186 |
|
44 |
39 |
$984.06 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
13 |
13 |
$957.00 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
203 |
172 |
$776.21 |
| 84702 |
|
193 |
154 |
$625.43 |
| 83605 |
|
770 |
627 |
$537.88 |
| 83690 |
|
494 |
448 |
$527.55 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
16 |
15 |
$397.58 |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
169 |
158 |
$281.80 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
133 |
116 |
$208.40 |
| 85610 |
|
28 |
25 |
$48.58 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
488 |
449 |
$42.21 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
40 |
37 |
$5.02 |
| 86140 |
|
252 |
225 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
37 |
24 |
$0.00 |
| 85379 |
|
39 |
37 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
14 |
13 |
$0.00 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
17 |
14 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
14 |
13 |
$0.00 |